Recombinant anti-TNFα monoclonal antibody (Wuhan Institute of Biological Products)

重组全人源抗人TNF-α单克隆抗体（武汉生物制品研究所）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-TNFα monoclonal antibody (Wuhan Institute of Biological Products)
Drug Alias Name重组全人源抗人TNF-α单克隆抗体注射液
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesWuhan Institute Of Biological Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Institute Of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A